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Purpose: To discuss the evolution of noninvasive diagnostic methods in the identifica-
tionof choroidal nevus anddeterminationof risk factors formalignant transformation as
well as introduce the novel role that artificial intelligence (AI) can play in the diagnostic
process.
Methods:White paper.
Results: Longstanding diagnostic methods to stratify benign choroidal nevus from
choroidal melanoma and to further determine the risk for nevus transformation into
melanoma have been dependent on recognition of key clinical features by ophthalmic
examination. These risk factors have been derived from multiple large cohort research
studiesover thepast several decades andhavegarneredwidespreaduse throughout the
world. More recent publications have applied ocular diagnostic testing (fundus photog-
raphy, ultrasound examination, autofluorescence, and optical coherence tomography)
to identify risk factors for the malignant transformation of choroidal nevus based on
multimodal imaging features. The widespread usage of ophthalmic imaging systems
to identify and follow choroidal nevus, in conjunction with the characterization of
malignant transformation risk factors via diagnostic imaging, presents a novel path to
apply AI.
Conclusions:AI applied to existing ophthalmic imaging systems could be used for both
identification of choroidal nevus and as a tool to aid in earlier detection of transforma-
tion to malignant melanoma.
Translational Relevance: Advances in AI models applied to ophthalmic imaging
systems have the potential to improve patient care, because earlier detection and treat-
ment of melanoma has been proven to improve long-term clinical outcomes.
Copyright 2021 The Authors
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Introduction
Choroidal nevus is the most common primary
intraocular tumor.1 Based on several studies, the
overall prevalence of choroidal nevus in the adult
population ranges from 5% to 25%.2–7 Choroidal
nevus is often found incidentally on routine ophthalmic
funduscopic examination. This lesion typically occurs
as a well-circumscribed pigmented or nonpigmented
lesion, residing deep to the retina within the choroid
and measuring <2 mm in thickness and <5 mm
in diameter. This lesion carries two important risks,
including vision loss, particularly if the mass is
subfoveal; more important, a benign nevus can trans-
form into malignant melanoma, with the potential for
melanoma-related metastasis and death.
Similar to a cutaneous nevus, a choroidal nevus
can slowly change over time and such change might
not necessarily be a harbinger of malignant transfor-
mation. In 2008, Shields et al.8 evaluated 3422 eyes
with choroidal nevus and found that the following
parameters change over time, including number of nevi
per eye, nevus thickness, and nevus-related overlying
drusen. In addition, choroidal nevus can slowly and
minimally enlarge over time and still maintain benign
behavior. Mashayekhi et al.9 documented that 31% of
choroidal nevi demonstrate slight enlargement over 7
to 10 years without clinical evidence of transformation
into melanoma and this is more often noted in younger
compared to older patients.
Choroidal nevus can be divided into low risk and
high risk for future growth into melanoma based
on clinical features. Low risk clinical features include
overlying drusen or retinal pigment epithelial (RPE)
alterations, both implying a long-standing mass with
overlying chronic degeneration (Fig. 1). In 1995, an
early study showed high-risk clinical features to include
thickness of >2 mm, the presence of overlying subreti-
nal Fluid, presence of Symptoms, presence of overly-
ing Orange pigment, and tumor location near the
optic disc Margin, which can be remembered by
the mnemonic “To Find Small Ocular Melanoma”
(TFSOM) (Fig. 2).10 In 2000, various combinations
of high-risk features were evaluated, with the great-
est risk for transformation into melanoma at 63%,
found with the combination of three features, includ-
ing a thickness of >2 mm, the presence of subretinal
fluid, and a tumor margin near the optic disc.11 A later
follow-up study of >2500 choroidal nevi continued to
refine the high risk clinical factors for transformation
into melanoma including greater Thickness, subretinal
Fluid, Symptoms, Orange pigment, Margin near disc,
and additionally with three new features: Ultrasound
Hollowness, absence of Halo and absence of Drusen,
creating a new mnemonic “To Find Small Ocular
Melanoma - Using Helpful Hints Daily” (TFSOM -
UHHD). A combination of any three factors posed a
mean risk of >50% for transformation.12
Singh et al.13 calculated the rate for transforma-
tion of choroidal nevus into melanoma in the United
States population at 1 in 8845, but with the assump-
tion that all choroidal melanoma arises from a preex-
isting nevus, which might not be the case. Kivelä and
Eskelin14 calculated that the lifetime risk for transfor-
mation of nevus to melanoma by age 80 years of age
approached 1%. Therefore, the over-riding goal is to
detect choroidal nevus and follow periodically (semian-
nually or annually) for evidence of risk factors for
transformation or for documentation of growth into
melanoma, both necessitating intervention with eradi-
cation of the lesion. If the pigmented lesion is choroidal
melanoma at the time of detection, identification of
the tumor at a tiny or small stage would be ideal as
increasing size increases the risk for metastasis (Fig. 3).
Shields et al.15 reviewed 8033 cases of uveal melanoma
and noted that each millimeter of increasing thick-
ness added a 5% risk for melanoma metastasis at 10
years (Fig. 4). For example, a melanoma measuring 0
to 1mm thickness demonstrated approximately 5% rate
of metastasis, those measuring 4 to 5 mm thickness
showed approximately 25% rate, and those of ≥10 mm
showed a >50% rate of metastasis.15 Clinical recogni-
tion and detection of small melanoma is key to preven-
tion of metastasis and death. There is no known cure
for metastasis.
What HaveWe Learned from
Cutaneous Melanoma?
The word melanoma causes one to think of skin
(cutaneous) melanoma. Approximately 90% to 95%
of all melanomas are found in the skin. Cutaneous
melanoma is well-publicized and is increasing in
frequency, mostly owing to overexposure to solar
radiation. Cutaneous melanoma also has the potential
to lead to metastasis and death. Cutaneous melanoma
generally arises on sun-exposed areas of the body,
with ultraviolet radiation exposure being the main risk
factor for development.16–19 Lesser known, the eye
(uvea [iris, ciliary body, and choroid]) is the second
most frequent location of malignant melanoma in
the body, representing about 5% of all melanomas.
Although cutaneous and uveal melanoma are two
distinct diseases and one does not lead to the other,
both occur most often in patients with fair skin
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Figure 1. Spectrum of benign choroidal nevus. (A) Choroidal nevus (arrow) near the optic disc with overlying RPE atrophy. (B) Choroidal
nevus (arrow) nasal to the optic disc with overlying and dependent RPE atrophy. (C) Choroidal nevus (arrow) inferotemporal to the macula
with surrounding yellow halo. (D) Large choroidal nevus (arrow) nasal to the optic disc with overlying yellow drusen.
complexion and blue or green eyes. Uveal melanoma
has not clearly been found to be related to sunlight
exposure, but similar to cutaneous melanoma, uveal
melanoma can arise from a preexisting nevus or de
novo.16 For both diseases, early detection is key for
survival.
In 2004, Lindholm et al.17 documented that early
cutaneous melanoma (<1 mm in thickness) had a
5-year survival of rate of 94% and this decreased
to 49% in those with a thickness of >4 mm.
Major advances in the dermatology (skin) litera-
ture have helped in early detection of cutaneous
melanoma. The mnemonic ABCDE (Asymmetry,
Border irregularity, Color, Diameter >6 mm, Evolv-
ing size, shape, or color) simplified the key features
of early cutaneous melanoma and helped physicians
and nonphysicians diagnose suspicious lesions before
they grew.18 Skin self-examination has helped to
improve the early detection of cutaneous melanoma.19
Further advances with the use of instruments like
dermoscopy, a handheld device that allows magni-
fied, high-resolution visualization of the skin, has also
improved detection.20 Automated computer-assisted
differentiation has provided 95% sensitivity and 70%
specificity.20
Malignant melanoma of the eye occurs in the uveal
tissue, which encompasses the iris, ciliary body, and
choroid. This tract is a specialized vascularized tissue
that manifests pigmented melanocytes, the source of
nevus and melanoma. Uveal melanoma, similar to
cutaneous melanoma, can metastasize to distant parts
of the body and lead to death.21 Current treatments
for uveal melanoma include enucleation (removal of
the eye), different forms of radiotherapy, local resec-
tion of the tumor, thermal laser, and novel therapies,
still in development, using nanoparticles.22
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Figure 2. Multimodal imaging of benign choroidal nevus. (A) Choroidal nevus (arrow) with overlying yellow drusen. (B) Autofluorescence
demonstrating the ring-shaped, minimally bright signal (arrow) of drusen. (C) OCT showing dark nevus with low signal (white arrow) and
overlying pigment epithelial detachment (yellow arrow). (D) Ultrasound examination showing flat nevus (arrow) with<2 mm thickness.
Clinical Significance
Uveal melanoma most often arises in the choroid
and often from a preexisting choroidal nevus. This
nevus may be clinically apparent at an earlier age prior
to malignant transformation, allowing for the possibil-
ity of early detection and intervention based upon risk
factors associated with the nevus. The natural occur-
rence of a nevus in the eye is far more common than
melanoma.2,3
In the past, before multimodal ophthalmic imaging
was available, diagnostic risk factors were based
on subjective clinical observations alone.10–12 These
factors were refined over decades of research to
more accurately identify melanoma at an earlier
stage in transformation, with the goal of diagnos-
ing and treating melanoma at the smallest possi-
ble size.12 More recently, high-resolution multimodal
ophthalmic imaging has become available and has
been studied for identification of objective risk factors
for nevus transformation into melanoma.22–24 These
objective imaging factors hold the same goal as subjec-
tive clinical risk factors, but with the added benefit
of reproducibility and availability with documenta-
tion and seem to be more reliable as findings are
measurable.
Ophthalmic diagnostic imaging generally allows
for direct photographic imaging of extraocular and
intraocular surfaces, including all boundaries of
choroidal nevus and melanoma, as well as cross-
sectional imaging of the mass via ultrasound exami-
nation and optical coherence tomography (OCT), the
former approaching 150 microns of resolution in
tissue and the latter with high resolution down to
10 microns. Imaging of the RPE is available with
autofluorescence, a technique using light wave filters
to detect lipofuscin within the RPE and represented
with bright signal (overabundance of lipofuscin, found
with small melanoma) or dark signal (underabun-
dance of lipofuscin, found with chronic nevus damage
to the RPE) (Figs. 2 and 4). Direct imaging of
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Figure3. Spectrumofmalignant choroidalmelanoma. (A) Small choroidalmelanoma (arrow)withoverlyingorangepigment. (B) Elongated
choroidal melanoma (arrow) with overlying orange pigment on the inferior aspect. (C) Dome-shaped choroidal melanoma (arrow) with
central elevated nodule. (D) Large choroidal melanoma (arrow) with overlying subretinal fluid.
ocular blood flow is also possible by intravenous injec-
tion of contrast agents, fluorescein angiography, and
indocyanine green angiography. Fluorescein angiogra-
phy can detect modifications in the internal and exter-
nal blood-retinal barriers, which may help in differ-
entiating large choroidal nevi from small choroidal
melanomas. In contrast, indocyanine green angiogra-
phy is mainly used to study intratumoral vasculariza-
tion and can be beneficial in the differentiation between
small amelanotic choroidal tumors, including choroidal
nevi, choroidal melanoma, choroidal hemangiomas,
and small isolated metastatic tumors. Noninvasive flow
detection is possible with OCT angiography, using only
light stimulated OCT images and applying a decorre-
lation algorithm to detect flow changes and with ultra-
sound examination using Doppler color flowmapping.
Although OCT angiography can detect modifications
of the superficial and deep capillary plexus of the
retina, its use in the differential diagnosis between
choroidal nevus and melanoma is currently limited.23
Several imaging modalities, including ultrasound
examination, autofluorescence, and OCT, were
combined to evaluate a series of 3806 choroid nevi.24,25
Using multimodal ophthalmic imaging, objective risk
factors for nevus transformation into melanoma
have been identified including Thickness >2 mm
(ultrasound examination), subretinal Fluid (OCT),
Symptoms (Snellen visual acuity loss to ≤20/50),
Orange pigment (autofluorescence), Melanoma acous-
tic hollowness (ultrasound examination), and tumor
DIaMeter >5 mm (fundus photography) (Figs. 2 and
4).24,25 Based on these recent findings, the mnemonic
for choroidal nevus transformation to melanoma
was updated to “To Find Small Ocular Melanoma
Doing IMaging” to reflect the importance of integrat-
ing objective imaging modalities into the clinical
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Figure 4. Multimodal imaging of malignant choroidal melanoma. (A) Choroidal melanoma (arrow) with overlying orange pigment. (B)
Autofluorescence demonstrating the intense bright signal (arrow) of orange pigment. (C) OCT showing dark melanoma with low signal
(white arrow) and overlying subretinal fluid (yellow arrow). (D) Ultrasound examination showing elevated melanoma (arrow) with acoustic
hollowness, thickness >2 mm, and shallow subretinal fluid.
assessment of these tumors. As with clinical risk
factors, the mean 5-year rate for nevus growth to
melanoma increases as more multimodal imaging
features are positive, because any two factors promotes
a mean 22% risk, three factors show 34% risk, and four
factors promote >50% risk for transformation.24,25
Potential for Artificial Intelligence (AI)
Applications
The long-standing use of clinically identified
risk factors in differentiating choroidal nevus from
melanoma10,12,26 and the more recent extensive use
of ophthalmic diagnostic imaging to both identify
and monitor choroidal nevus and melanoma22,24–27
provide substantial data to begin to identify potential
applications of AI.
AI is an interdisciplinary field of research developed
out of the postulation by McCarthy et al. in the invita-
tion to the Dartmouth Artificial Intelligence Confer-
ence in 1956 that “every aspect of learning or any other
feature of intelligence can in principle be so precisely
described that a machine can be made to simulate
it.”28
Machine learning (ML) is a conceptual approach
to computational analysis that developed out of the
field of AI. ML is an AI technique that can be used
to design and train software algorithms to learn from
and act on.29 ML uses computer algorithms to gener-
alize from datasets and continue to perform accurately
on future data sets without further programming. The
algorithms used can differ in approach, based on the
data sets and the application. They can be super-
vised, where the algorithm is trained on human-labeled
data, or unsupervised, where the algorithm is trained
on unlabeled data and will search for patterns by
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itself,30 as well as numerous other methods of learning
and model creation. Supervised learning and models
tend to be excellent classifiers of disease type (e.g.,
nevus vs. no nevus) and disease stage (e.g., low-risk
vs. high-risk nevus).30 For instance, a supervised ML
model can be trained with a dataset consisting of
labeled fundus photographs of choroidal nevi and
photographs of the normal fundus. The trained model,
through supervised learning, may eventually be able
to identify a nevus in a fundus photograph, with a
sufficiently high level of accuracy, that is sensitivity
and specificity. For the model to achieve high levels
of accuracy, a large dataset of fundus photographs
of choroidal nevi is required so that the model can
identify any choroidal nevus regardless of shape, size
(small vs. large), location (macular vs. extramacular),
degree of pigmentation (pigmented vs. nonpigmented),
as well as nevus associated with a variety of clinical
features (subretinal fluid, orange pigment, overlying
drusen, overlying RPE atrophy, RPE hyperplasia, or
RPE fibrosis). Another supervised ML model can be
trained with a separate dataset of fundus photographs
of choroidal nevi labeled as low risk or high risk
based on high-risk clinical features identified on
fundus examination (presence of overlying subretinal
fluid, presence of overlying orange pigment, diameter
of >5 mm).
Deep learning is a highly specialized artificial neural
network subtype of ML that consists of layers of
algorithms forming complex neural networks inspired
by the ones constituting the human brain.30 This
allows deep learning algorithms to self-iterate with the
goal of improved performance and accuracy the more
data they explore, a major advantage over classic ML
algorithms that eventually reach a plateau.30 Because
of convolutional layers and the overall architectural
structure of deep learning systems, this technology
allows models to not only be excellent classifiers of
disease but also excellent feature extractors.30
In theory, an unsupervised deep learning model can
be trained with unlabeled photographs of the normal
fundus as well as photographs of various choroidal
nevi with a range of risk factors for malignant trans-
formation. A deep learning algorithm’s process of
progressive, layered data extraction allows the model
to infer qualities from the input fundus photographs
and cluster them based on computational features and
then further identify patternswithin those features and,
perhaps, learn not only to identify a nevus, but also to
classify it based on risk of malignant transformation.
In this regard, deep learning algorithms hold the poten-
tial to find novel or unexpected computational features
that might predict nevus at risk for malignant transfor-
mation.
Of note, true color fundus photographs are often
chosen as initial training data for the ML models.
With the advent of wide-field digital true color fundus
cameras, a single photograph is enough in most cases
to capture a choroidal nevus with its associated clini-
cal features in contrast to the other ophthalmic imaging
modalities such as OCT and OCT angiography where
often a series of cuts are needed to capture the entire
lesion. This allows for easier labeling of the data as
well as faster training of the ML model. In addition,
training of future ML models can be expanded to
include pseudocolor fundus photographs as this carries
the potential of providing AI assistance where clini-
cal expertise might be needed the most, such as in
optometry offices where pseudocolor fundus photo-
graph cameras are often used for patient screening.
Recently, the US Food and Drug Administra-
tion (FDA) has cleared or approved several digital
health technologies. InApril 2018, the FDAauthorized
the first stand-alone diagnostic system, the Diabetic
Retinopathy Detection Device (IDx-DR), designed to
automatically detect the presence of more-than-mild
diabetic retinopathy.31
There are also FDA-cleared systems for use in breast
cancer detection including QuantX,32 for computer-
aided imaging diagnosis detection granted in July 2017
and MammoScreen,33 a radiologic computer-assisted
software for lesions suspicious for cancer, cleared by
FDA in March 2020. Recently, the FDA granted the
“breakthrough” designation to 3Derm Spot34 for the
evaluation of skin images to autonomously detect
cutaneous melanoma, squamous cell carcinoma and
basal cell carcinoma. A full list of devices authorized
for marketing including 510(k) “premarket notifica-
tion” and “de novo” are available in the FDA search-
able medical device database.35 The FDA’s Center for
Devices and Radiological Health the embraces devel-
opment of digital health technologies which, include
AI, ML, deep learning, and other types of software
systems, known as Software as a Medical Device.
Implementing the Center for Devices and Radiologi-
cal Health’s latest policies for digital health technolo-
gies will facilitate innovation in Software as a Medical
Device for diagnosis of choroidal nevus and prediction
of risk for malignant transformation.
Despite the potential of AI models in the diagnosis
of choroidal nevus and prediction of risk for malignant
transformation, there remains a number of challenges
that should be considered, including the homogeneity
of the training dataset, the potential of deep learn-
ing models to be black boxes, and the use of two-
dimensional images that lack stereoscopic qualities.36
Using fundus photographs taken with a specific digital
fundus camera with a preset width of field, image
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magnification, and resolution, and from patients of
similar race could add bias to the results, preclud-
ing their generalizability and the use of the model
in different clinical settings.30 A technical challenge
of reliance solely on fundus photographs arises from
their two-dimensional nature. Without stereo fundus
photographs or focus differential data, the aspect of
thickness is greatly diminished. This is an important
imaging feature, which was found to be a signifi-
cant predictor for malignant transformation through-
out all previous studies by Shields et al.10–12,24,25
However, AI might detect other features that could
serve as a surrogate for thickness. Finally, consider-
ing the longstanding clinical diagnostic process, the
potential that AI and deep learning can base risk
of malignant transformation on nonspecific compu-
tational features36 might raise questions among clini-
cians that will necessitate resolution before full accep-
tance of the models. Although challenges will need to
be addressed, the potential benefits of AI and ML is
substantial, especially with continued development of
neural networks, more refinedmodels and higher confi-
dence in the results.37
Conclusions
The concept of AI-based screening of ophthalmic
imaging for both the presence of choroidal nevus and
the factors that suggest potential transformation into
melanoma would greatly enhance the detection and
early treatment of melanoma within the eye. Guided
by the understanding that, based on melanoma size at
the time of treatment, smaller melanoma (earlier detec-
tion) portends a better life prognosis, this early detec-
tion has the potential to save lives.14,38,39
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